Overall, our findings indicate that, in addition to being an effective immune checkpoint blockade strategy, inhibition of the PD-1/PD-L1 axis may be a novel approach to decrease drug resistance in cancer and, therefore, improve the efficacy of chemotherapy. This evidence concerns the gene CD274 and cancer.